Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
Positive charges and the aromatic residues let it associate with cardiolipin. That is a membrane-lipid interaction, not an AMPK peptide and not carnitine.
It does not replace coenzyme Q or carnitine. The target is the lipid, not a receptor in the incretin sense.
Cardiolipin holds electron-transport complexes in the inner mitochondrial membrane. Elamipretide is designed to associate with that lipid and stabilize cristae in experimental systems.
The pathway is biophysical, at the membrane. It is not an incretin pathway and not a growth-hormone pathway.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Mitochondrial fatigue logs · unverified
Forums group elamipretide with MOTS-c and carnitine for fatigue. Cardiolipin binding is the specific mechanism. The logs rarely say that.
Theme summarized from public discussion. Not a quoted post, not a trial, and not a dose.